Locations:
Search IconSearch
April 18, 2023/Orthopaedics/Research

7 Insights for Orthopaedic Surgeons Building a Research Program

Cleveland Clinic’s Adult Reconstruction Research leaders share what they’ve learned over 16 years

Healing the world with passion and purpose

When Cleveland Clinic’s Adult Reconstruction Research (CCARR) Program began in 2007, it was a rare entity, the brainchild of former Cleveland Clinic orthopaedic surgeon Wael Barsoum, MD. Alison Klika, then doing orthopaedic bench research in Cleveland Clinic’s Lerner Research Institute, remembers the beginning.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Dr. Barsoum had a vision for a unique clinical research program, but he needed to build a team,” she says. “He had a small bit of corporate money and one resident, James Rosneck, MD, now staff at Cleveland Clinic Sports Medicine Center and team physician for the Cleveland Cavaliers. Dr. Rosneck conducted joint reconstruction research as part of his training. Dr. Barsoum needed someone with writing and publishing experience, so he brought me in. It was initially just the three of us. I didn’t even have a job title.”

Klika, now the program manager, has seen the research group grow over the past 16 years.

“Back then, I was writing grants, submitting proposals for corporate funding, conducting research, analyzing the stats and whatever else was needed,” she says. “Now there are nearly a dozen of us who specialize in different functions. Our group has become a machine. We’ve gone from publishing five or 10 manuscripts a year, if we were lucky, to publishing more than 100 in 2022.”

The current CCARR team includes a basic and translational lead scientist, three research coordinators, a data analyst, two research fellows (with a two-year commitment) and multiple medical students (with a one-year commitment), all led since 2018 by Director Nicolas S. Piuzzi, MD, of Cleveland Clinic’s Department of Orthopaedic Surgery.

“We have 10-15 prospective clinical trials in progress at any given time — including leading large multicenter studies — in addition to conducting multiple retrospective research and other studies,” says Dr. Piuzzi. “Our vision to advance personalized patient care through evidence-based orthopaedic practice has led us to collaborate with most major orthopaedic centers in the U.S. and around the world.”

Advertisement

In this interview, Dr. Piuzzi and Klika explain more about the structure of their group and offer guidance for orthopaedic surgeons interested in building clinical research programs of their own.

What makes Cleveland Clinic’s Adult Reconstruction Research Program so unique?

Dr. Piuzzi: Cleveland Clinic has one of the broadest practices in joint replacement, with numerous providers and partners in a high-volume, high-complexity environment. Add to that a team dedicated solely to advancing joint arthroplasty through research. That combination is exceptional.

Our uniqueness, however, is our team structure, which has been evolving and maturing over more than a decade. Many CCARR team members have been added and have become more proficient in each step of the research process. All of us have a shared mission: to improve the outcomes of hip and knee arthroplasty patients through personalized medicine and evidence-based orthopaedic surgery. That mission is why we have invested resources in training residents and research fellows; embedded a data analyst in our group; and recruited a PhD to lead our basic and translational research projects, including developing an animal model for studying biofilm and infection prevention.

Klika: We build relationships outside of our group as well, such as with biostatisticians, legal experts and clinical partners who refer patients for trials. Most of our funding comes from corporate relationships. The fact that we’ve been able to build this effort out of corporate funding, as well as some philanthropic support and foundation grants, and maintain it for 16 years is also unique.

Advertisement

Your opinion piece in JAMA Surgery back in 2020 talked about a lag in incorporating evidence-based care in orthopaedic surgery. Why does that lag exist?

Dr. Piuzzi: This problem is not unique to orthopaedic surgery. It applies to most surgical subspecialties. Randomized controlled trials, which can provide the best evidence of the value of an intervention, are challenging to execute in a surgical environment. Blinding surgeons and surgical patients is nearly impossible, providing sham surgeries for a control group is unethical, and the logistics of randomized controlled trials are complex.

While many surgical interventions are already proven by empirical evidence or just the proof of time, there are many things for which we don’t have good evidence. There are gaps in our treatment protocols for certain conditions or disease stages.

Our goal in CCARR is to identify an evidence-based approach for each of these gaps. For example, we have a big gap with infection, so we need to create a strategic focus area within our program to answer questions about infection. We have a gap in understanding patients who have complications or do not improve after joint replacement, so we need to create a strategic focus area for personalized medicine to optimize patients and tailor treatments for them. We have a challenge in revision arthroplasty, in creating stable and long-lasting implants that can survive years and years after multiple revision surgeries. We need to create a strategic focus area to study that.

Gaps like these are why we need more orthopaedic research and more groups to do it.

So, the field of orthopaedic surgery needs more large, prospective randomized controlled trials?

Dr. Piuzzi: Yes, but not just large prospective trials. We need more research of all kinds. For example, if we wanted to study joint replacement in patients with a left ventricular assist device due to heart failure, it would be extremely hard to do a randomized controlled trial because there are so few patients in the world who would qualify for it. We couldn’t recruit enough patients in a reasonable amount of time. In that scenario, the best available data might come from a retrospective case series or cohort.

Advertisement

For even more unique scenarios, a case study might provide great value.

Randomized controlled trials and systematic reviews of those trials are the strongest scientific evidence you can get, but each type of research provides value.

Not every orthopaedic surgeon or practice has the resources to conduct the breadth of research that we do. But everybody could have some level of involvement in different tiers of research, contributing in some way to our field. Having an open-minded, question-driven approach makes everyone’s clinical practice better.

What are the clinical benefits of having a research program?

Dr. Piuzzi: Our work has a direct and positive impact on Cleveland Clinic patients — and hopefully patients around the world. We use our research findings to create models and tools that we test and validate not just for ourselves but for the entire field.

One great example is the predictive modeling that we have developed based on collected patient data, such as mental health status and socioeconomic status. We can predict how long a patient will stay in the hospital, their chance of being discharged to a skilled nursing facility rather than home, and their chance of being readmitted within 30 or 90 days. We have personalized risk profiles that guide how we take care of each patient. If we identify high risk in someone, we recommend resources to help reduce it.

Klika: The work of our research team is what made those models possible, in collaboration with our clinical partners, programmers and electronic medical record specialists. We don’t just publish the research; we incorporate it into our clinical workflows. Another example is our partnership with Cleveland Clinic’s rehabilitation programs that aid post-acute care transitions after total joint arthroplasty. Those transitions were developed with support from our research, guiding discharge disposition after surgery. Data collected by our group provides a starting point for conversations with all kinds of patient care teams.

Advertisement

For orthopaedic providers interested in forming their own research program, what does it take?

Dr. Piuzzi: In April 2021, we published an overview in EFORT Open Reviews of how to build a “team that lasts” in orthopaedic clinical research. There are seven main takeaways from that article:

  1. Surgeons don’t do it alone. It takes an organized team of individuals with varying roles and skills. Any professional with a medical license can serve as a primary investigator (PI), the leader responsible for how a certain study is conducted and how its findings are communicated. A surgeon leading a research program does not need to be the PI on all of the studies undertaken. You can collaborate with other providers in your practice, having them serve as a PI on studies that interest them. The PI is always supported by non-physician staff, including research coordinators. Research coordinators oversee the daily administrative tasks, such as enrolling patients and ensuring compliance with data collection regulations. Coordinators are the main contact for study participants. Having a program manager is helpful when you have multiple research coordinators to oversee and findings from multiple studies to disseminate.
  2. Research training is a must. Training team members can involve mentoring and other on-the-job experiences. However, formal research education is available through organizations such as the Collaborative Institutional Training Initiative, the Association of Clinical Research Professionals, the Society of Clinical Research Associates and the American Academy of Orthopaedic Surgeons. Certification programs for research team members are available but not mandatory.
  3. Strong leadership by PIs and research managers is fundamental. These research leaders are responsible for building mutual trust and respect among team members. They lead by serving, making decisions in the best interest of the team. One of the most important decisions is selecting new research projects. Leaders must establish a process for vetting and approving projects. The process should involve a checklist to consider regulatory, ethical, operational and other issues that may arise, and to ensure your site and staff can successfully carry out each project.
  4. A solid team culture helps promote stability and employee satisfaction. Work settings and funding sources differ between academic and private institutions. All can offer benefits for the careers of research team members. No matter the opportunities and challenges inherent in an organization, research leaders can ensure their team members are compensated in line with market rates and offered opportunities to grow professionally. Increasing employee satisfaction and retaining team members long term improves the stability of a research program and helps research projects run smoothly.
  5. Legal experts and grant administrators can help secure funding. Funding availability and budgeting strategies vary by organization. Learn from your organization’s legal and grant teams what types of grants are available for your research program and how to apply for them.
  6. All research team members must understand and comply with government and industry regulations. No matter their role, each person on the team is responsible for ensuring good clinical practice, including protecting the rights, safety and welfare of clinical trial participants. An institutional review board must approve all research protocols and ensure team members are trained properly. Aside from good clinical practice, other regulations, such as disclosure of physicians’ financial relationships, also must be followed.
  7. Communication strengthens the team. Research programs require a great deal of collaboration among surgeons, research coordinators, data analysts, grant administrators, legal experts, research fellows and other team members. Interpersonal and communication skills are valuable. Frequent, informal meetings, welcoming an open exchange between team members, can help build team rapport and efficiency. It is important to commit to weekly (or more frequent) team meetings to discuss study progress and roadblocks.

We provide more guidance on all these elements in the full article. To sum it up, successful programs start with one surgeon committed to advancing orthopaedics through research, who is willing to share that vision with others and build a team to make that vision a reality. It takes a team.

Related Articles

An open wound in a patient's armpit
Atypical Presentations of Periprosthetic Shoulder Infection

Sinus tracts can occur years later and not near the incision site

neurons, axons and synapses in the brain
September 5, 2024/Neurosciences/Research
A Case Study in Neurotherapeutic Clinical Trial Design and Conduct

New phase 1 trial showcases Neurological Institute’s interdisciplinary study capabilities

Dr. Grobmyer and team
June 14, 2024/Cancer/Innovations
Fatima bint Mubarak Center Addresses Inequities in Cancer Care

Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

Treating older patients with diffuse large B-cell lymphoma (DLBCL)
January 18, 2024/Cancer/Blood Cancers
Trial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps Address Care Inequities

Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients

Close-up of natural pattern on cannabis leaf
August 28, 2023/Orthopaedics/Hip & Knee
Cannabis Use May Increase Risk of Complications After Total Joint Arthroplasty

Study findings warrant caution in patients at risk for DVT, cardiovascular issues and more

23-NEU-3810710-CQD-Hero-650×450
Clinicians Emphasize Harm Reduction When Counseling Patients About the Use of Psychedelics

Growing public interest in hallucinogens highlights their therapeutic promise and potential perils

Ad